Vaccine

Details Vaccine Vaccine

2007-08-14

2007-08-14

Minnifield, N. M. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S237100, C424S234100, C424S236100, C424S185100, C424S193100, C424S450000, C424S454000, C424S283100, C424S197110, C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

10706275

ABSTRACT:
Effective stimulation of immune responses is achieved through the use of a group A streptococcal antigen combined with proteosome adjuvant. The compositions are provided in particular for intranasal administration. The vaccine compositions are provided for use in inducing an immune response in an individual for the treatment or prophylaxis of group A streptococcal infection in an individual, preferably via prevention or reduction of colonisation of the throat following intranasal administration.

REFERENCES:
patent: 4454121 (1984-06-01), Beachey
patent: 4521334 (1985-06-01), Beachey
patent: 4597967 (1986-07-01), Beachey
patent: 4695562 (1987-09-01), Beachey et al.
patent: 4705684 (1987-11-01), Beachey
patent: 4707543 (1987-11-01), Zollinger et al.
patent: 4728639 (1988-03-01), Beachey
patent: 4919930 (1990-04-01), Beachey et al.
patent: 5124153 (1992-06-01), Beachey et al.
patent: 5162226 (1992-11-01), Beachey et al.
patent: 5716637 (1998-02-01), Anselem et al.
patent: 5726292 (1998-03-01), Lowell
patent: 5961970 (1999-10-01), Lowell et al.
patent: 5965390 (1999-10-01), Bjorck et al.
patent: 5985284 (1999-11-01), Lowell
patent: 6063386 (2000-05-01), Dale et al.
patent: 6174528 (2001-01-01), Cooper et al.
patent: 6419932 (2002-07-01), Dale
patent: 6476201 (2002-11-01), Lowell et al.
patent: 6716433 (2004-04-01), Dale
patent: 6737521 (2004-05-01), Fischetti et al.
patent: 6743900 (2004-06-01), Burt et al.
patent: 6803042 (2004-10-01), Lowell
patent: 6822075 (2004-11-01), Bjorck et al.
patent: 7060277 (2006-06-01), Kaempfer et al.
patent: 7189398 (2007-03-01), Kaempfer et al.
patent: 2002/0086023 (2002-07-01), Dale
patent: 2002/0176863 (2002-11-01), Dale
patent: 2003/0143245 (2003-07-01), Reddish et al.
patent: 2003/0157122 (2003-08-01), Dale
patent: 2005/0002956 (2005-01-01), Lowell et al.
patent: 2005/0042230 (2005-02-01), Anderson et al.
patent: 2005/0063988 (2005-03-01), Dale
patent: 2005/0152919 (2005-07-01), Ward et al.
patent: 2005/0202037 (2005-09-01), Dale
patent: 2006/0222650 (2006-10-01), Kaempfer et al.
patent: 0 305 279 (1989-03-01), None
patent: WO 90/15872 (1990-12-01), None
patent: WO 93/21220 (1993-10-01), None
patent: WO 94/06421 (1994-03-01), None
patent: WO 94/06465 (1994-03-01), None
patent: WO 96/11944 (1996-04-01), None
patent: WO 97/10844 (1997-03-01), None
patent: WO 98/01558 (1998-01-01), None
patent: WO 98/34968 (1998-08-01), None
patent: WO 99/13084 (1999-03-01), None
patent: WO 99/52939 (1999-10-01), None
patent: WO 00/37648 (2000-06-01), None
patent: WO 00/40729 (2000-07-01), None
patent: WO 01/60402 (2001-08-01), None
patent: WO 02/057315 (2002-07-01), None
patent: WO 02/072012 (2002-09-01), None
patent: WO 03/065973 (2003-08-01), None
patent: WO 2004/098636 (2004-11-01), None
patent: WO 2005/007189 (2005-01-01), None
patent: WO 2005/027964 (2005-03-01), None
patent: WO 2005/042017 (2005-05-01), None
Lowell et al, Technological Advances in Vaccine Development, 1988, pp. 423-432.
Olive et al, Vaccine, 2002, 20:2816-2825.
Hayman et al, Immunology and Cell Biology, 2002, 80:178-187.
Batzloff et al, Indian J. Med. Res., May 2004, 119/Suppl:104-107.
Toth et al, PEPTIDES 2002, pp. 634-635.
Musser et a al, Infection and Immunity, Mar. 1995, 63/3:994-1003.
Berge et al, JBC, 1993, 268/34:25417-25424.
Podbielski et al, Med. Microbiol. Immunol., 1992, 181:209-213.
Collins et al, Infection and Immunity, 1992, 60/9:3689-3696.
Smirnov et al, Gene, 1992, 120:27-32.
Hall et al, Infection and Immunity, May 2004, 72/5″2507-2512.
Whatmore et al, Molecular Microbiology, 1994, 14/4:619-631.
Lesinki et al, Abstracts of Gener al Meeting American Society for Microbiology, 2001, 101:341 abstract only.
Bessen et al, Infection and Immunity, 1988, 56/10:2666-2672.
Brandt et al, International Immunology, 1999, 11/4:569-576.
Brandt et al, Nature Medicine, 2000, 6/4:455-459.
Brandt et al, Immunology, 1996, 89:331-337.
Hayman et al, International Immunology, 1997, 9/11:1723-1733.
Relf et al, Advances in Exptal. Med. and Biol., 1997, 418(Streptococci and the Host):859-861.
Fox et al J. Clinical Investigation, 1973, 52:1885-1892.
Bessen et al, J. Immunology, 1990, 145/4:1251-1256.
Horvath et al, J. Med. Chem., 2004, 47:4100-4104.
Olive et al, Infection and Immuinty, 2002, 70/5:2734-2738.
Brandt et al, Infection and Immunity, 2000, 68/12:6587-6594.
Dunn et al, Vaccine, 2002, 20:2635-2640.
Lesinski et al, Vaccine, 2001, 19:1717-1726.
Dale, Vaccine, 1999, 17:193-200.
Olive et al, Vaccine, 2005, 23:2298-2303.
Srivastava et al, Hybridoma, 2000, 19/1:23-31.
Relf et al, Peptide Research, 1996, 9/1:12-20.
Lowell et al, Infection and Immunity, 1996, 64/5:1706-1713.
Kaminski et al, 94thASM General Meeting, 1994, 94/0:155 Abstract #E-70 Abstract only.
Lowell et al, Trans. Royal Soc. Trop. Med. and Hyg., 1989, 83/Suppl:101-102.
Bhattacharjee et al, J. Infectious Diseases, 1996, 173:1157-1163.
Dasleg et al, Vaccines, 1996, pp. 177-182.
Fries et al, Infection and Immunity, 2001, 69/7:4545-4553.
Plante et al, International Congress Series, 2001, 1219:979-984.
Ruegg et al, J. Immunological Methods, 1990, 135:101-109.
Mallett et al, Infection and Immunity, 1995, 63/6:2382-2386.
Lowell et al, Infection and Immunity, 1996, 64/11:4686-4693.
Lowell et al, Science, 1988, 240:800-802.
Levi et al, Vaccine, 1995, 13/14:1353-1359.
Lynch et al, Biophys. J. 1984, 45:104-107.
Lowell, In: New Generation Vaccines, ed. Levine et al, 1997 Marcel Dekker, Inc., pp. 193-206.
Lowell et al, J, Expt. Medicine, 1988, 167:658-663.
Cunningham, Clinical Microbiology Reviews, 2000, 13/3:470-511.
Dale, Infect. Dis. Clin. North Am., 1999, 13/1:227-243 abstract only.
Dale et al, Infection and Immunity, 2002, 70/4:2166-2170.
Pruksakorn et al, J. Immunology, 1992, 149/8:2729-2735.
Hu et al, Infection and Immunity, 2002, 70/4:2171-2177.
Dale et al, J. Clin. Invest., 1999, 103/9:1261-1268.
Bronze, M. S. et al., “Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses,”The Journal of Immunology, 148(3):888-893, Feb. 1, 1992.
Cartwright, K., “Group A streptococcal infections in humans,”Journal of Applied Microbiology Symposium, 83(Suppl.):52S-61S, 1997.
Guzman, C. A. et al., “Protective immune response againstStreptococcus pyogenesin mice after intranasal vaccination with Fibronectin-Binding protein Sfbl,”The Journal of Infectious Diseases, 179(4):901-906, Apr. 1999.
Janulczyk, R. et al., “Identification and characterization of aStreptococcus pyogenesABC transporter with multiple specificity for metal cations,”Molecular Microbiology, 34(3):596-606, 1999.
Ji, Y. et al., “Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by group AStreptococcus,” Infection and Immunity, 65(6):2080-2087, Jun. 1997.
Johnsson, E. et al, “Role of hypervariable region in streptococcal M proteins: Binding of a human complement inhibitor,”The Journal of Immunology, 161(9):4894-4901, 1998.
Kehoe, M. A. et al., “Horizontal gene transfer among group A streptococci: implications for pathogenesis and epidemiology,”Trends in Microbiology, 4(11):436-443, Nov. 1996.
Pruksakorn, S. et al., “Identification of T-cell autoepitopes that cross-react with the C- terminal segment of the M protein of group A streptococci,”International Immunology, 6(8):1235-1244, 1994.
Pruksakorn, S. et al., “Towards a vaccine for rheumatic fever: identification of a conserved target epitope on M protein of group A streptococci,”The Lancet, 344:639-642, Sep. 3, 1994.
Robinson, J. H. and Kehoe, M. A., “Group A streptococcal M proteins: virulence factors and protective antigens,”Immunology Today, 13(9):362-367, 1992.

Affiliated with

Also associated with

Rating

Vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3840302